Product Quality ‘Wild Card’? Sarepta’s Gene Therapy Manufacturing Process Change Means More Empty Capsids

 
• By Sue Sutter

SRP-9001 intended for commercialization is not analytically comparable to the product used in earlier clinical studies; FDA CMC reviewer said agency does not mandate the extent of empty or full capsids but, instead, looks at the totality of data to assess safety and efficacy.

Joker playing card 2
Product quality differences resulting from a manufacturing change for SRP-9001 represents an efficacy and safety wild card, one panelist said. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers